Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.
Saved in:
| Title: | Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes. |
|---|---|
| Authors: | Merz AMA; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany., Sébert M; Service Hématologie Séniors, Hôpital Saint-Louis (AP-HP), Paris Cité University and INSERM U944, Paris, France., Sonntag J; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany., Kubasch AS; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany., Platzbecker U; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany. Electronic address: uwe.platzbecker@medizin.uni-leipzig.de., Adès L; Service Hématologie Séniors, Hôpital Saint-Louis (AP-HP), Paris Cité University and INSERM U944, Paris, France. Electronic address: lionel.ades@aphp.fr. |
| Source: | Cancer treatment reviews [Cancer Treat Rev] 2024 Feb; Vol. 123, pp. 102673. Date of Electronic Publication: 2023 Dec 19. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
